Floatz logo

Sitravatinib

Nonpapillary Renal Cell Carcinoma

Explore 112 assets in Nonpapillary Renal Cell Carcinoma →
Floatz Rating
B57/100
Confidence
Indicative
v0.2
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT04904302CT.gov
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
—Terminated———
NCT04518046CT.gov
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
—Completed———
NCT03680521CT.gov
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
—Completed———
NCT03015740CT.gov
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Nonpapillary Renal Cell Carcinoma

AssetSponsorPhaseRating
Sitravatinib (this asset)M.D. Anderson Cancer CenterP2B · 57
GirentuximabMassachusetts General HospitalP3BB
Clostridium Butyricum Miyairi 588City of Hope Medical CenterP3BB
PazopanibAcademic and Community Cancer Research UnitedP4BB
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsP2BB
NivolumabFred Hutchinson Cancer CenterP3BB
CabozantinibSWOG Cancer Research NetworkP3BB
IrinotecanM.D. Anderson Cancer CenterP3B
CyclophosphamideCity of Hope Medical CenterP3B

+42 more in the Nonpapillary Renal Cell Carcinoma cohort

Other indications for Sitravatinib

IndicationSponsorPhaseRating
Renal Cell Carcinoma—P2CCC · 55
Metastatic Malignant Neoplasm—P2/3CCC · 54
Non-Small Cell Lung Carcinoma—P3CCC · 52

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Sitravatinib in Nonpapillary Renal Cell Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/sitravatinib-nonpapillary-renal-cell-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →